- Trials with a EudraCT protocol (852)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
852 result(s) found for: Rheumatoid Arthritis.
Displaying page 10 of 43.
EudraCT Number: 2007-006603-20 | Sponsor Protocol Number: C1377T04 | Start Date*: 2009-07-29 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcut... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000710-42 | Sponsor Protocol Number: RR-xx-RTX-COVAC | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Sint Maartenskliniek | |||||||||||||
Full Title: The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dose and vaccination timing. A prospective cohort study. | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004931-39 | Sponsor Protocol Number: ALD518-CLIN-003 | Start Date*: 2008-12-08 | |||||||||||
Sponsor Name:Alder Biopharmaceuticals, Inc | |||||||||||||
Full Title: A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80 mg, 160 mg, and 320 mg ALD518 versus Placebo Administered as Multiple Intravenous Infusions to Patients with Active Rheumatoid ... | |||||||||||||
Medical condition: Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014394-41 | Sponsor Protocol Number: WRAP | Start Date*: 2009-10-12 | |||||||||||
Sponsor Name:Hvidovre Hospital | |||||||||||||
Full Title: Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and s... | |||||||||||||
Medical condition: Reumatoid artritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006007-15 | Sponsor Protocol Number: JAKAR | Start Date*: 2022-09-01 | |||||||||||
Sponsor Name:Leiden University Medical Center (LUMC) | |||||||||||||
Full Title: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis | |||||||||||||
Medical condition: patients with ACPA-positieve active RA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002573-62 | Sponsor Protocol Number: ClinTrid-US-1201 | Start Date*: 2012-10-12 | |||||||||||
Sponsor Name:The Karolinska Institute, ClinTRID | |||||||||||||
Full Title: Doppler quantitative evaluation and follow-up over 12 months in RA patients with moderate and high disease activity who are candidates for biologic add-on therapy with Adalimumab | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003162-13 | Sponsor Protocol Number: WI232128 | Start Date*: 2019-01-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA | |||||||||||||
Full Title: A Study to investigate Bone turnover Markers in patients planned to receive tofacitinib | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003341-18 | Sponsor Protocol Number: DSC/11/2357/42 | Start Date*: 2011-10-14 | |||||||||||
Sponsor Name:Italfarmaco S.p.A. | |||||||||||||
Full Title: An Open-Label Extension of the Dose Finding study (DSC/08/2357/36) in patients with polyarticular course Juvenile Idiopathic Arthritis (poly JIA) | |||||||||||||
Medical condition: Polyarticular course Juvenile Idiopathic Arthritis (poly JIA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006741-70 | Sponsor Protocol Number: FARM7Y279L | Start Date*: 2008-10-16 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Comparison of the efficacy of intrarticular corticosteroid therapy administered alone or in combination with methotrexate in children with juvenile idiopatic arthritis: a phase II, randomized actic... | |||||||||||||
Medical condition: juvenile idiopatic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001097-25 | Sponsor Protocol Number: ML25756 | Start Date*: 2011-10-19 | |||||||||||
Sponsor Name:Roche Pharma AG | |||||||||||||
Full Title: Long-term, interventional, open label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Germany who completed t... | |||||||||||||
Medical condition: Polyarticular-course juvenile idiopathic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002809-12 | Sponsor Protocol Number: YLB113-002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:YL Biologics Ltd | |||||||||||||
Full Title: A comparative Study to Assess the Efficacy, Safety and Immunogenicity of YLB113 and Enbrel for the Treatment of Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) CZ (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011206-42 | Sponsor Protocol Number: INCB 28050-201 | Start Date*: 2009-08-18 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate... | |||||||||||||
Medical condition: Active Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016119-38 | Sponsor Protocol Number: 20090402 | Start Date*: 2010-05-19 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis. | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) LV (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003280-40 | Sponsor Protocol Number: A720B20 | Start Date*: 2009-06-30 | ||||||||||||||||
Sponsor Name:Public Health Service Amsterdam | ||||||||||||||||||
Full Title: Response to hepatitis A and B vaccine among children with immunesuppression due to either hiv or immunesuppressive medication | ||||||||||||||||||
Medical condition: The effectiveness of Ambirix will be investigated in 2 groups: 1) children with hiv-infection, with CD4 counts > 15% 2) children with a rheumatic disease for which immune-suppressive medication is ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000089-35 | Sponsor Protocol Number: DSC/05/2357/19 | Start Date*: 2006-08-17 | |||||||||||
Sponsor Name:ITALFARMACO | |||||||||||||
Full Title: Phase II, open label, international, multicentre clinical trial to investigate safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idiopathic arthritis SOJIA | |||||||||||||
Medical condition: systemic onset juvenile idiopathic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002326-63 | Sponsor Protocol Number: CDP870-050 | Start Date*: 2005-09-21 | |||||||||||
Sponsor Name:UCB Celltech | |||||||||||||
Full Title: A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SK (Completed) CZ (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023692-26 | Sponsor Protocol Number: D4300C00004 | Start Date*: 2011-04-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: (OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab M... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001350-24 | Sponsor Protocol Number: CDP870-028 | Start Date*: 2005-05-31 | |||||||||||
Sponsor Name:UCB Celltech | |||||||||||||
Full Title: A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilised CDP870 an engineered human anti-TNF PEG conjugate, dosed subcutaneously at 400 ... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) CZ (Completed) HU (Completed) LT (Completed) EE (Completed) LV (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005320-81 | Sponsor Protocol Number: CACZ885A2201E2 | Start Date*: 2008-10-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid ar... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) ES (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002339-27 | Sponsor Protocol Number: I4V-MC-JADX | Start Date*: 2013-01-14 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying A... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) IT (Completed) PT (Completed) GB (Completed) CZ (Completed) SK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
